Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
MARITIME-HF-20230227
Obesity and Heart Failure Phase III
- 12 weeks
NETTER-3 (CAAA601A62301)
Oncology: GEP-NET Phase III
- 8 weeks
- 2nd site activated worldwide
panSOHO
HER2 Solid Tumors Phase II
- 10.8 weeks
- 1st site activated in Canada
PDY18663
Graves' disease Phase II
- 7.2 weeks
PRESTO
Pulmonary Disease Phase IIb
- 5.2 weeks
PRESTO
Pulmonary Disease Phase IIb
- 8 weeks
WO45654
Breast Cancer Phase III
- 9.2 weeks
- 1st site activated in Canada
WO45654
Breast Cancer Phase III
- 9 weeks
WO45654
Breast Cancer Phase III
- 11 weeks
WO45654
Breast Cancer Phase III
- 17.4 weeks
WO45654 (Inavo123)
Breast Cancer Phase III
- 8.2 weeks
- 1st site activated in Canada
WO45654 (Inavo123)
Breast Cancer Phase III
- 9 weeks
WO45654 (Inavo123)
Breast Cancer Phase III
- 11 weeks
WP45335
Hematology – Von Willebrand Disease Phase Non-Interventional
- 15.2 weeks
WP45338
Hematology - Von Willebrand Disease Phase III
- 13.6 weeks
- 1st site activated in Canada
1479-0009
Solid Tumors Phase II
- 10.8 weeks
- 1st site activated in Canada
1479-0009
Solid Tumors Phase II
- 10 weeks
- 3rd site activated in Canada
20230153
Non-Small Cell Cancer (NSCLC) Phase II
- 8 weeks
- 1st site activated in Canada
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 12.4 weeks
- 1st site activated in Canada and 2nd site activated worldwide
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 10.6 weeks
- 2nd site activated in Canada
ACT18064 (RESULT)
Focal Segmental Glomerulosclerosis (FSGS) Phase I
- 4.4 weeks